These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18039422)

  • 41. Sex differences in the drug therapy for oncologic diseases.
    Schmetzer O; Flörcken A
    Handb Exp Pharmacol; 2012; (214):411-42. PubMed ID: 23027461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine kinase inhibitors in veterinary medicine.
    London CA
    Top Companion Anim Med; 2009 Aug; 24(3):106-12. PubMed ID: 19732728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
    Levitzki A; Klein S
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of biological responses of colorectal cancer cells to anticancer regimens.
    Roh SA; Choi EY; Cho DH; Yoon YS; Kim TW; Kim YS; Kim JC
    J Korean Surg Soc; 2012 Jul; 83(1):21-9. PubMed ID: 22792530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.
    Vaziri SA; Kim J; Ganapathi MK; Ganapathi R
    Curr Oncol Rep; 2010 Mar; 12(2):102-8. PubMed ID: 20425594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
    Labots M; Van der Mijn JC; Dekker H; Ruijter R; Pham TV; Van der Vliet HJ; Van der Hoeven JJM; Meijer GA; Verheul HMW
    Oncologist; 2018 Oct; 23(10):1135-e118. PubMed ID: 30018133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.
    Bologna M; Vicentini C; Muzi P; Pace G; Angelucci A
    Curr Med Chem; 2011; 18(19):2827-35. PubMed ID: 21651496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting tyrosine-kinases in ovarian cancer.
    Morotti M; Becker CM; Menada MV; Ferrero S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1265-79. PubMed ID: 23815710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors.
    Moradpour Z; Barghi L
    J Pharm Pharm Sci; 2019; 22(1):37-48. PubMed ID: 30636671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.
    Merla A; Goel S
    Chemother Res Pract; 2012; 2012():387172. PubMed ID: 23097702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Impact on budget of new drugs for colorectal cancer treatment].
    Corral MJ; Clopès A; Navarro M; Germà JR; Borràs JM
    Med Clin (Barc); 2007 Jun; 129(4):134-6. PubMed ID: 17663967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.
    Adebayo AS; Agbaje K; Adesina SK; Olajubutu O
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New agents for colorectal cancer.
    Mulcahy ME; Benson AB
    J Natl Compr Canc Netw; 2003 Jan; 1(1):125-36. PubMed ID: 19764156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Individualized dosing of tyrosine kinase inhibitors: are we there yet?
    de Wit D; Guchelaar HJ; den Hartigh J; Gelderblom H; van Erp NP
    Drug Discov Today; 2015 Jan; 20(1):18-36. PubMed ID: 25245169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of advanced colorectal cancer: state of the art.
    Saunders M; Iveson T
    Br J Cancer; 2006 Jul; 95(2):131-8. PubMed ID: 16835584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.
    Carethers JM
    Therap Adv Gastroenterol; 2008 Jul; 1(1):33-42. PubMed ID: 21180512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of systemic therapies for locally advanced and metastatic rectal cancer.
    Yaffee P; Osipov A; Tan C; Tuli R; Hendifar A
    J Gastrointest Oncol; 2015 Apr; 6(2):185-200. PubMed ID: 25830038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer.
    Iyer KK; van Erp NP; Tauriello DVF; Verheul HMW; Poel D
    Cancer Treat Rev; 2022 Nov; 110():102466. PubMed ID: 36183569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
    Abueg KD
    Clin J Oncol Nurs; 2014 Dec; 18(6):714-6. PubMed ID: 25427707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current topics and the clinical effects of target-based antineoplastic agents.
    Maehara Y; Egashira A; Kakeji Y
    Int J Clin Oncol; 2006 Jun; 11(3):164-6. PubMed ID: 16850121
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.